Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 12, 2012 - Issue 4
Submit an article Journal homepage
491
Views
18
CrossRef citations to date
0
Altmetric
Drug Evaluations

Rituximab for chronic lymphocytic leukemia

Tadeusz RobakMedical University of Lodz, Lodz, [email protected]
Pages 503-515 | Published online: 28 Feb 2012

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Tadeusz Robak, Anna Wolska & Pawel Robak. (2015) Potential breakthroughs with investigational drugs for hairy cell leukemia. Expert Opinion on Investigational Drugs 24:11, pages 1419-1431.
Read now
Piotr Smolewski & Tadeusz Robak. (2015) The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Drug Discovery 10:7, pages 791-808.
Read now
Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2015) Emerging immunological drugs for chronic lymphocytic leukemia. Expert Opinion on Emerging Drugs 20:3, pages 423-447.
Read now
Tadeusz Robak. (2014) Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Review of Hematology 7:6, pages 841-857.
Read now
Tadeusz Robak & Pawel Robak. (2014) Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 14:5, pages 651-661.
Read now
Morag Meriel Griffin & Nick Morley. (2013) Rituximab in the treatment of non-Hodgkin's lymphoma – a critical evaluation of randomized controlled trials. Expert Opinion on Biological Therapy 13:5, pages 803-811.
Read now
Preetesh Jain & Susan O'Brien. (2013) Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opinion on Biological Therapy 13:2, pages 169-182.
Read now

Articles from other publishers (11)

Josée Golay. (2017) Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?. Journal of Autoimmunity 85, pages 6-19.
Crossref
Altacílio Aparecido Nunes, Anderson Soares da Silva, Kathiaja Miranda Souza, Christine de Nazaré Silva Koury & Luane Marques de Mello. (2015) Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis. Critical Reviews in Oncology/Hematology 94:3, pages 261-269.
Crossref
Hung Chang & Lee-Yung Shin. (2018) Chronic Lymphocytic Leukemia-associated Refractory Immune Thrombocytopenia Successfully Treated with Eltrombopag. Tumori Journal 101:2, pages e49-e50.
Crossref
Mohammad Hojjat-Farsangi. (2015) Novel and emerging targeted-based cancer therapy agents and methods. Tumor Biology 36:2, pages 543-556.
Crossref
Claire Fabre, Marco Gobbi, Cyrine Ezzili, Mustapha Zoubir, Marie-Paule Sablin, Karen Small, Ellie Im, Nabeegha Shinwari, Da Zhang, Honghong Zhou & Christophe Le Tourneau. (2014) Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology 74:5, pages 1057-1064.
Crossref
Karl-Josef Kallen & Andreas Theß. (2013) A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Therapeutic Advances in Vaccines 2:1, pages 10-31.
Crossref
Josée GolayFabio Da RoitLuca BolognaClaudia Ferrara, Jeanette H. Leusen, Alessandro RambaldiChristian Klein & Martino Introna. (2013) Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 122:20, pages 3482-3491.
Crossref
Rebecca Voltan, Paola Secchiero, Barbara Ruozi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli & Giorgio Zauli. (2013) Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. Clinical Cancer Research 19:14, pages 3871-3880.
Crossref
Tadeusz Robak. (2013) Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncology 9:1, pages 69-91.
Crossref
Marij J.P. Welters & Sjoerd H. van der Burg. 2013. Cancer Immunotherapy. Cancer Immunotherapy 241 258 .
Tadeusz Robak. (2012) Przeciwciała monoklonalne w leczeniu przewlekłej białaczki limfocytowej. Acta Haematologica Polonica 43:2, pages 99-106.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.